High-dose bicalutamide monotherapy for the treatment of prostate cancer

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 44-47

  Blackledge, George R P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL;

ANDROGEN ANTAGONISTS; ANILIDES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0029559165     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80008-2     Document Type: Article

References (9)

1. Furr BJ. Casodex: preclinical studies. Eur Urol 18 (suppl 3): 2-9, 1990.
2. Newling DW: The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase 11 study of Casodex. European/Australian Cooperative Group. Eur Urol 18 (suppl 3): 18-21, 1990.
3. Iversen P: Update of monotherapy trials with the new antiandrogen, Casodex (ICI 176,334). Eur Urol 26 (suppl 1): 5-9, 1994.
4. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, and Denis L: The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 18 (suppl 3): 10-17, 1990.
5. Denis L: A new non-steroidal anti-androgen. Prog Clin Biol Res 303: 95-103, 1989.
6. Kaisary AV, Tyrell CJ, Beacock C, Lunglmayr G, and Debruyne F: Casodex: an acceptable monotherapy for advanced prostate cancer? Preliminary results of a randomized trial against castration. Urology 587-590, 1992.
7. Schellhammer P, Scharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 45: 745-752, 1995.
8. Mahler C, Verhelst J, and Denis L: Preclinical and clinical experience with new antiandrogens in prostate cancer. Excerpta Medica International Congress Series (1064): 137-148, 1994.
9. Liebertz C, Kelly WK, Theodoulou M, Curley T, Dean L, Moyumdar M, Vlanis V, Scher HI: High-dose Casodex for prostate cancer (PC): PSA declines in patients with flutamide withdrawal responses (abstract 603). Proceedings of American Society of Clinical Oncology, 31st Annual Meeting May 20-23, 1995, vol 14, March 1995.